# EDGAR Filing Document

**Accession Number:** 0001460702
**File Stem:** 0001493152-23-002034
**Filing Date:** 2023-1
**Character Count:** 6173
**Document Hash:** 58216ae8ac8c54dd53b064ee6370985e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002034.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0001493152-23-002034

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230113

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Qualigen Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001460702
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263474527
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37428
- **FILM NUMBER:** 23541404

**BUSINESS ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011
- **BUSINESS PHONE:** (760) 918-9165

**MAIL ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RITTER PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090402

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 13, 2023**

**Qualigen Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37428** | **26-3474527** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

2042 Corte Del Nogal, Carlsbad, California 92011

(Address of principal executive offices) (Zip Code)

(760) 918-9165

(Registrant's telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, par value $.001 per share | QLGN | The Nasdaq Capital Market of The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

**Item 5.02. Departure of Directors or Certain Oﬃcers; Election of Directors; Appointment of Certain Oﬃcers; Compensatory Arrangements of Certain Oﬃcers.**

On January 13, 2023, the board of directors (the "Board") of Qualigen Therapeutics, Inc. (the "Company"), as part of certain cost-cutting measures, approved a temporary 20% reduction to the base salaries of all executive officers of the Company, including Michael Poirier, the Company's Chief Executive Officer, Christopher Lotz, the Company's Chief Financial Officer, Amy Broidrick, the Company's President and Chief Strategy Officer (also a named executive officer), Shishir Sinha, the Company's Chief Operating Officer and Senior Vice President, Diagnostics, and Tariq Arshad, the Company's Chief Medical Officer (also a named executive officer), effective immediately. The amendments to such executive officers' executive employment agreements or offer letters, as applicable, will be filed as exhibits to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2022.

As part of such cost cutting measures, on January 17, 2023, the Company provided notice to Mr. Sinha that his employment with the Company would be terminated effective February 16, 2023 (the "Effective Date").

Ms. Broidrick's title will become President, Chief Strategy and Operating Officer, effective as of the Effective Date. Ms. Broidrick's full biography and other information required by Item 5.02(c) of Form 8-K are included in the Company's proxy statement for its 2022 Annual Meeting of Stockholders, filed with the U.S. Securities and Exchange Commission on July 13, 2022 under the section titled "Board of Directors and Corporate Governance", and such information is incorporated herein by reference.

**Item 8.01. Other Events.**

As part of the cost-cutting measures described in Item 5.02 of this Current Report on Form 8-K, the Board also approved a temporary 20% reduction to the non-employee directors' annual cash compensation, and the elimination of the Company's position of Vice President and Chief Scientific Officer, currently held by Wajdi Abdul-Ahad, along with several other non-executive positions, effective January 17, 2023.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | QUALIGEN THERAPEUTICS, INC. | QUALIGEN THERAPEUTICS, INC. |
| Date: January 20, 2023 | By: | */s/ Michael S. Poirier* |
|  |  | Michael S. Poirier, Chief Executive Officer |

---